Investigational New Drugs View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1983

PUBLISHER

Springer US

LANGUAGE

en

HOMEPAGE

https://link.springer.com/journal/10637

Recent publications latest 20 shown

  • 2022-07-28 Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study
  • 2022-07-14 Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport
  • 2022-07-14 Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
  • 2022-07-14 Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study
  • 2022-07-08 First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
  • 2022-07-08 Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma
  • 2022-07-07 3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors
  • 2022-07-06 Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines
  • 2022-07-06 Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
  • 2022-07-05 Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients
  • 2022-07-05 Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
  • 2022-06-30 Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
  • 2022-06-29 First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
  • 2022-06-28 Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
  • 2022-06-27 A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
  • 2022-06-27 MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer
  • 2022-06-27 Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel
  • 2022-06-24 Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
  • 2022-06-21 A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer
  • 2022-06-21 Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "alternateName": "Novel Anti-Cancer Therapeutics and Therapies", 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.8550000190734863", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.253999948501587", 
            "type": "Rating"
          }
        ], 
        "description": "

    The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

    Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

    Investigational New Drugs cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.

    ", "editor": [ { "familyName": "Rowinsky", "givenName": "Eric K.", "type": "Person" } ], "id": "sg:journal.1094201", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0167-6997", "1573-0646" ], "license": "Hybrid", "name": "Investigational New Drugs", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "94201" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn 84009586" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "8309330" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "442160" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "14781" ] } ], "publisher": { "name": "Springer US", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1094201" ], "sdDataset": "journals", "sdDatePublished": "2022-08-04T17:25", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/journal/journal_0.jsonl", "startYear": "1983", "type": "Periodical", "url": "https://link.springer.com/journal/10637" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1094201'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1094201'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1094201'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1094201'


     

    This table displays all metadata directly associated to this object as RDF triples.

    61 TRIPLES      21 PREDICATES      28 URIs      24 LITERALS      10 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1094201 schema:alternateName Novel Anti-Cancer Therapeutics and Therapies
    2 schema:contentRating N778b0921100a4a91a0988bb330238939
    3 N90e56a36cbed41af9a624bf849a6ea6b
    4 schema:description <p>The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. <i>Investigational New Drugs</i> provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. <i>Investigational New Drugs</i> provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.<br/><br/>Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.<br/><br/><i>Investigational New Drugs</i> cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.</p>
    5 schema:editor N215e1f61f0fe4e60bfa6806ca23839c3
    6 schema:inLanguage en
    7 schema:isAccessibleForFree false
    8 schema:issn 0167-6997
    9 1573-0646
    10 schema:license Hybrid
    11 schema:name Investigational New Drugs
    12 schema:productId N07759ecce1f449f3a8cb0e99304c3f79
    13 N23c9be9d39a44bf48813ab9277e7ad25
    14 N9ae5f23c380c45b3b904c4495f423a2a
    15 Ne2cb635803b3471c866a47cac11228d5
    16 Nf3759aa99ccb48039f4d8c3f7122123c
    17 schema:publisher N84f9382f867e473eb0b4f738771c8494
    18 schema:publisherImprint Springer
    19 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1094201
    20 schema:sdDatePublished 2022-08-04T17:25
    21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    22 schema:sdPublisher Nec3114817508427098395d8cbcbe4d0d
    23 schema:startYear 1983
    24 schema:url https://link.springer.com/journal/10637
    25 sgo:license sg:explorer/license/
    26 sgo:sdDataset journals
    27 rdf:type schema:Periodical
    28 N07759ecce1f449f3a8cb0e99304c3f79 schema:name lccn_id
    29 schema:value sn 84009586
    30 rdf:type schema:PropertyValue
    31 N215e1f61f0fe4e60bfa6806ca23839c3 rdf:first Nfe10cb8271bf4834b1e1ff042a0b22c6
    32 rdf:rest rdf:nil
    33 N23c9be9d39a44bf48813ab9277e7ad25 schema:name era_ids_id
    34 schema:value 14781
    35 rdf:type schema:PropertyValue
    36 N6a9e835e78fb41f593a62c2d073a6c09 rdf:first sjr
    37 rdf:rest rdf:nil
    38 N778b0921100a4a91a0988bb330238939 schema:author N6a9e835e78fb41f593a62c2d073a6c09
    39 schema:ratingValue 1.253999948501587
    40 rdf:type schema:Rating
    41 N82c0693e7474486e86689862ef881faa rdf:first snip
    42 rdf:rest rdf:nil
    43 N84f9382f867e473eb0b4f738771c8494 schema:name Springer US
    44 rdf:type schema:Organization
    45 N90e56a36cbed41af9a624bf849a6ea6b schema:author N82c0693e7474486e86689862ef881faa
    46 schema:ratingValue 0.8550000190734863
    47 rdf:type schema:Rating
    48 N9ae5f23c380c45b3b904c4495f423a2a schema:name dimensions_id
    49 schema:value 94201
    50 rdf:type schema:PropertyValue
    51 Ne2cb635803b3471c866a47cac11228d5 schema:name nsd_ids_id
    52 schema:value 442160
    53 rdf:type schema:PropertyValue
    54 Nec3114817508427098395d8cbcbe4d0d schema:name Springer Nature - SN SciGraph project
    55 rdf:type schema:Organization
    56 Nf3759aa99ccb48039f4d8c3f7122123c schema:name nlm_unique_id
    57 schema:value 8309330
    58 rdf:type schema:PropertyValue
    59 Nfe10cb8271bf4834b1e1ff042a0b22c6 schema:familyName Rowinsky
    60 schema:givenName Eric K.
    61 rdf:type schema:Person
     




    Preview window. Press ESC to close (or click here)


    ...